Welcome to our dedicated page for Absci news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci stock.
Absci Corp (ABSI) combines generative AI with synthetic biology to accelerate therapeutic discovery. This news hub provides investors and industry professionals with essential updates on the company's advancements in AI-driven drug development, strategic collaborations, and platform innovations.
Access verified press releases covering key milestones including research breakthroughs, partnership announcements, and financial developments. Our curated collection enables efficient tracking of Absci's progress in optimizing biologic drug creation through its Integrated Drug Creation™ platform.
Explore updates across critical categories: AI technology enhancements, pharmaceutical partnerships, therapeutic pipeline developments, and financial performance. Each update maintains factual accuracy while highlighting Absci's unique position at the intersection of computational biology and drug discovery.
Bookmark this page for direct access to primary source materials and official announcements. Regularly updated content ensures stakeholders stay informed about Absci's contributions to oncology, immunology, and next-generation biologic therapies.
Absci Corporation (Nasdaq: ABSI) reported its financial results for Q4 and the full year 2021, highlighting a significant increase in R&D and administrative expenses. Revenue for Q4 was $1.5 million, down from $2.7 million in Q4 2020. For the full year, revenue remained stable at $4.8 million. R&D expenses surged to $44.6 million from $11.4 million year-over-year, contributing to a net loss of $101 million for 2021. Despite these challenges, Absci made strides by initiating collaborations with Merck and NVIDIA and expects to launch eight new Active Programs in 2022.
Absci Corporation (Nasdaq: ABSI) announced advancements in its in-silico drug discovery technology during a presentation at NVIDIA GTC. The company focuses on machine learning models for therapeutic antibodies, aiming for a seamless pipeline from target identification to drug candidate creation. Breakthroughs include a model predicting antibody target affinity and a scoring system for the 'naturalness' of antibody variants, enhancing their developability. Collaborating with NVIDIA aims to further accelerate this innovative platform, with potential implications for the drug discovery industry.
Absci Corporation has appointed Andreas Busch, PhD, to its Board of Directors, enhancing its leadership in drug discovery.
Dr. Busch brings over 20 years of experience, previously serving as EVP and Chief Scientific Officer at Shire and Head of Drug Discovery at Bayer.
His expertise is expected to bolster Absci's efforts in in-silico design of therapeutic proteins as the company advances its unique Integrated Drug Creation™ Platform.
Absci Corporation (Nasdaq: ABSI) announced that Lead AI Scientist Joshua Meier will present at NVIDIA GTC on March 22, 2022, at 1:00 p.m. PT. The session focuses on leveraging deep learning and synthetic biology for drug and target discovery. Attendees can register for free to join the virtual presentation at NVIDIA's official site.
Absci aims to expand the therapeutic potential of proteins using its Integrated Drug Creation™ Platform, partnering with biotech and pharma innovators to develop the next generation of protein-based drugs.
Absci Corporation (Nasdaq: ABSI) announced that CEO Sean McClain will participate in the Synthetic Biology Enabling Drug Discovery Panel at the Cowen 42nd Annual Health Care Conference. The event is set for March 8, 2022, from 12:30-1:30 p.m. Pacific Time / 3:30-4:30 p.m. Eastern Time. A live and archived webcast will be available on the company’s investor relations website.
Absci leverages deep learning AI and synthetic biology in drug discovery, aiming to advance the therapeutic potential of proteins.
Absci Corporation (Nasdaq: ABSI), a pioneer in drug and target discovery utilizing deep learning AI, announced its participation in two upcoming virtual investor conferences. The Truist Life Sciences AI Symposium will feature a panel discussion on March 1, 2022, at 7:10 a.m. PT, while the Cowen 42nd Annual Health Care Conference will include a fireside chat on March 7, 2022, at 9:50 a.m. PT. Interested attendees can access these events through the provided links. These engagements highlight Absci's commitment to expanding the therapeutic potential of proteins and facilitating drug development.
Absci Corporation (Nasdaq: ABSI) will participate virtually in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 8:30 a.m. Pacific Time. The company specializes in drug and target discovery by leveraging deep learning AI and synthetic biology, aiming to enhance the therapeutic potential of proteins. Absci's Integrated Drug Creation™ Platform allows the identification of novel drug targets and the discovery of optimal biotherapeutic candidates in a streamlined process. For more information, visit www.absci.com.
Absci Corporation (Nasdaq: ABSI) has announced a research collaboration with Merck to utilize its AI-driven Integrated Drug Creation™ Platform. This partnership will employ Absci's Bionic Protein™ technology to develop tailored enzymes for Merck's biomanufacturing needs. Absci can earn up to $610 million in milestone payments for three nominated drug targets, along with ongoing research funding and tiered royalties on sales. The collaboration aims to enhance the therapeutic potential of proteins and improve patient outcomes.
Absci Corporation (Nasdaq: ABSI) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10th at 12:45 p.m. PT / 3:45 p.m. ET. This presentation will be conducted virtually, and interested individuals can access a live and archived webcast through the company's website.
Absci specializes in drug and target discovery using deep learning AI and synthetic biology, aiming to advance protein therapeutic potential. For more information, visit www.absci.com.
Absci Corporation (Nasdaq: ABSI) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference on January 10th, 2022, at 4:00 a.m. Pacific Time. The company utilizes deep learning AI and synthetic biology for drug and target discovery, facilitating the development of protein-based drugs. Interested individuals can access the live and archived webcast through the investors' section on their website. With a focus on expanding therapeutic potential, Absci aims to transform innovative ideas into effective medicines.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
